Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
Oliver Klein, Damien Kee, Adnan Nagrial, Markman Ben, Craig Underhill, Michael Michael, Caroline Lum, Andreas Behren, Jodie Palmer, Niall C Tebbutt, Matteo S Carlino, Jonathan S Cebon
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
4588 Background: Patients (pts) with advanced biliary tract cancers (BTC) have a poor prognosis with first and second line chemotherapy resulting in modest survival benefits. Immunotherapy using single agent anti-PD-1 therapy has also shown low activity with an objective response rate (ORR) of less than 10%. Combined CTLA-4/PD-1 blockade using ipilimumab (ipi) and nivolumab (nivo) has demonstrated superior efficacy compared to single agent anti-PD-1 therapy in pts with advanced melanoma and renal cell carcinoma. To date, no trials in BTC pts with ipi/nivo therapy have been reported. Methods: 39 pts with metastatic BTCs were enrolled into the CA 209-538 clinical trial for rare cancers. Patie..View full abstract
Australian Federal Department of Health